Cancer cachexia is a wasting syndrome that causes severe, involuntary loss of muscle and fat tissue. It affects up to 74% of cancer patients and is directly responsible for 20 to 30% of all cancer deaths. Unlike ordinary weight loss from not eating enough, cachexia is driven by the cancer itself and cannot be fully reversed by eating more food.
How Cachexia Differs From Malnutrition
The distinction between cachexia and simple starvation is critical. When a healthy person loses weight from not eating, the body primarily burns fat stores and largely preserves muscle. Refeeding restores the lost weight. Cachexia works differently: the body breaks down both muscle and fat simultaneously, and increasing food intake does not recover the lost weight. Research confirms that the appetite loss and tissue wasting in cachexia are controlled by independent molecular mechanisms, meaning even patients who manage to eat more still lose muscle.
This happens because cachexia is fundamentally a metabolic disorder, not a nutritional one. Tumors trigger a state of chronic inflammation that raises basal metabolism, accelerates fat breakdown, suppresses fat production, and ramps up muscle protein destruction. The engine behind this process is the cancer itself, which releases substances that hijack the body’s normal signaling.
What Drives the Muscle and Fat Loss
Tumors produce a substance called proteolysis-inducing factor that switches on inflammatory pathways inside cells, triggering a cascade of signals that ultimately chew through muscle protein. At the same time, the cancer provokes the immune system into flooding the body with inflammatory molecules. These molecules attack muscle tissue through multiple routes at once: they activate protein-disposal systems inside muscle cells, they block the formation of new muscle fibers, and they reduce the energy-producing capacity of muscle cells by impairing their mitochondria.
The same inflammatory signals also act on the brain’s stress-response system, causing the release of cortisol, a hormone that independently promotes muscle breakdown. Fat tissue gets hit too. Inflammatory molecules activate enzymes that break stored fat into free fatty acids, depleting the body’s energy reserves even when caloric intake is adequate. The result is a patient who loses weight from every tissue compartment, not just one.
Which Cancers Cause It Most Often
Cachexia rates vary dramatically depending on the type of cancer. Pancreatic and gastric cancers are the worst offenders, with some studies reporting cachexia in 80 to 90% of patients. Gastroesophageal and pancreatic cancers collectively show rates of 60 to 70%. Lung cancer causes cachexia in about 60% of cases, while colorectal and blood cancers fall in the 40 to 50% range. Breast and prostate cancers sit at the lower end, around 20%.
The pattern reflects how aggressively certain tumors drive inflammation. Cancers of the digestive system tend to produce more of the inflammatory signals responsible for wasting, and they also directly interfere with nutrient absorption, compounding the problem.
The Three Stages
Cachexia progresses through three recognized stages, each defined by how much weight a patient has lost relative to their body size.
- Pre-cachexia: Weight loss of more than 1 kilogram but less than 5% of body weight. At this stage, early intervention has the best chance of slowing progression.
- Cachexia: Weight loss greater than 5%, or greater than 2% in someone who already has a low BMI (under 20) or reduced muscle mass.
- Refractory cachexia: Weight loss exceeding 15% with a BMI below 23, or exceeding 20% with a BMI below 27. At this point, the wasting is largely irreversible, and the focus shifts to comfort and quality of life.
Catching cachexia in the pre-cachexia or early cachexia stage matters because the destructive cycle becomes harder to interrupt as it advances. By the refractory stage, the metabolic changes are so deeply entrenched that the body can no longer respond meaningfully to treatment.
How Cachexia Undermines Cancer Treatment
Cachexia does not just weaken patients. It actively sabotages their ability to tolerate chemotherapy. Many chemotherapy drugs are metabolized in skeletal muscle, so when muscle mass drops, the drugs are processed differently. Doses calculated based on a patient’s body surface area may effectively become overdoses in someone with depleted muscle, leading to higher concentrations of toxic drugs circulating in the body.
A prospective study of gastrointestinal cancer patients found that cachexia was the strongest predictor of dose-limiting toxicities during chemotherapy, with a roughly tenfold increase in risk compared to patients without cachexia. Patients with cachexia experienced significantly more nausea, diarrhea, and appetite loss during treatment cycles. When chemotherapy side effects become severe enough, oncologists are forced to reduce doses or delay treatment cycles, both of which can compromise the cancer treatment’s effectiveness.
This creates a vicious cycle: the cancer causes cachexia, cachexia makes treatment harder to tolerate, and reduced treatment gives the cancer more room to grow, which worsens the cachexia further.
Current Treatment Options
There are currently no FDA-approved drugs specifically for cancer cachexia, which reflects how difficult the condition is to treat. Existing therapies can provide some relief but are not considered optimal. Management typically involves a combination of nutritional support, appetite-stimulating medications, exercise when feasible, and anti-inflammatory approaches, all aimed at slowing the progression rather than curing the syndrome.
Nutritional counseling and calorie-dense supplements help maintain energy intake but, as noted, cannot reverse the metabolic changes on their own. Physical activity, even at low intensity, can help preserve muscle function and improve quality of life, though it cannot fully counteract the protein breakdown driven by inflammation. Some patients benefit from medications that stimulate appetite or reduce inflammation, though responses vary widely.
One area of active investigation is a drug called ponsegromab, an experimental antibody being tested in combination with standard chemotherapy for metastatic pancreatic cancer. The ongoing trial, called RIVER-mPDAC, is evaluating whether targeting one of the molecular drivers of cachexia can improve outcomes when added to first-line treatment. Because ponsegromab is still experimental, it is only available through clinical trials.
Why Early Recognition Matters
Cancer cachexia remains poorly diagnosed despite affecting the majority of patients with certain tumor types. Part of the problem is that weight loss in cancer patients is often attributed to poor appetite, treatment side effects, or depression rather than recognized as a distinct metabolic syndrome requiring its own management. By the time cachexia becomes obvious, patients may already be in the refractory stage where intervention is least effective.
Tracking weight changes, muscle strength, and body composition early in a cancer diagnosis gives clinicians the best opportunity to intervene during the pre-cachexia window. For patients and caregivers, unexplained weight loss of more than 5%, persistent fatigue, and progressive weakness are the key signals that cachexia may be developing, even if appetite seems relatively normal.